Myriad Genetics, Inc. cash flow to debt ratio of 0.86% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Myriad Genetics, Inc.'s free cash flow has increased -33.33% from $-38.40M last year to $-25.60M, signaling increasing performance

Myriad Genetics, Inc.'s debt to equity ratio is 0.69, which means that the company's assets are unhealthy financed, signaling financial risk.

Myriad Genetics, Inc.'s debt has increased relative to shareholder equity from 0.20 last year to 0.69 today, signaling weakened financials

Myriad Genetics, Inc. has negative EBITDA, making leverage ratio unreliable

Myriad Genetics, Inc.'s interest coverage ratio is -5.68, which means that the company struggles to meet interest obligations, signaling financial risk.

Myriad Genetics, Inc.'s profit margin has increased (-8.15%) in the last year from -15.20% to -13.96%, signaling increasing performance

Myriad Genetics, Inc.'s short-term assets of $332.60M exceed its short-term liabilities of $133.80M

Myriad Genetics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Myriad Genetics, Inc.'s return on equity of -32.59%, is lower than 15.00%, indicating bad performance

Myriad Genetics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Myriad Genetics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Myriad Genetics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Myriad Genetics, Inc. has negative free cash flow, indicating cash burn

Myriad Genetics, Inc.'s yearly earnings has decreased 187.43% since last year from $-127.30M to $-365.90M, signaling decreasing performance

Myriad Genetics, Inc.'s yearly revenue has decreased 1.56% since last year from $837.60M to $824.50M, signaling decreasing performance

ROIC -18.08% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Myriad Genetics, Inc.'s 3-year revenue CAGR of 6.72% is positive, indicating growing revenue over the past 3 years

Myriad Genetics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Myriad Genetics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Myriad Genetics, Inc. has insufficient data to evaluate this check.

Myriad Genetics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Myriad Genetics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Myriad Genetics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Myriad Genetics, Inc. is overvalued relative to its fair value price of -29.83 based on Earnings Fair Value model

Myriad Genetics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Myriad Genetics, Inc. has a price-to-book ratio of 1.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Myriad Genetics, Inc. has a price-to-sales ratio of 0.38x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue